282 related articles for article (PubMed ID: 37385272)
1. Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial.
Ragni MV; Rothenberger SD; Feldman R; Nance D; Leavitt AD; Malec L; Kulkarni R; Sidonio R; Kraut E; Lasky J; Pruthi R; Angelini D; Philipp C; Hwang N; Wheeler AP; Seaman C; Machin N; Xavier F; Meyer M; Bellissimo D; Humphreys G; Smith KJ; Merricks EP; Nichols TC; Ivanco D; Vehec D; Koerbel G; Althouse AD
Lancet Haematol; 2023 Aug; 10(8):e612-e623. PubMed ID: 37385272
[TBL] [Abstract][Full Text] [Related]
2. Von Willebrand factor for menorrhagia: a survey and literature review.
Ragni MV; Machin N; Malec LM; James AH; Kessler CM; Konkle BA; Kouides PA; Neff AT; Philipp CS; Brambilla DJ
Haemophilia; 2016 May; 22(3):397-402. PubMed ID: 26843404
[TBL] [Abstract][Full Text] [Related]
3. Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions.
van Galen KP; Engelen ET; Mauser-Bunschoten EP; van Es RJ; Schutgens RE
Cochrane Database Syst Rev; 2015 Dec; (12):CD011385. PubMed ID: 26704192
[TBL] [Abstract][Full Text] [Related]
4. Phase II prospective open-label trial of recombinant interleukin-11 in women with mild von Willebrand disease and refractory menorrhagia.
Ragni MV; Jankowitz RC; Jaworski K; Merricks EP; Kloos MT; Nichols TC
Thromb Haemost; 2011 Oct; 106(4):641-5. PubMed ID: 21833452
[TBL] [Abstract][Full Text] [Related]
5. Non-surgical interventions for treating heavy menstrual bleeding (menorrhagia) in women with bleeding disorders.
Ray S; Ray A
Cochrane Database Syst Rev; 2014 Nov; (11):CD010338. PubMed ID: 25426776
[TBL] [Abstract][Full Text] [Related]
6. Non-surgical interventions for treating heavy menstrual bleeding (menorrhagia) in women with bleeding disorders.
Ray S; Ray A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD010338. PubMed ID: 27841443
[TBL] [Abstract][Full Text] [Related]
7. Oral micronised flavonoids versus tranexamic acid for treatment of heavy menstrual bleeding secondary to copper IUD use: a randomised double-blind clinical trial.
Alanwar A; Abbas AM; Hussain SH; Elhawwary G; Mansour DY; Faisal MM; Elshabrawy A; Eltaieb E
Eur J Contracept Reprod Health Care; 2018 Oct; 23(5):365-370. PubMed ID: 30247074
[TBL] [Abstract][Full Text] [Related]
8. An approach to outreach patients with von Willebrand disease in Egypt by targeting women with heavy menstrual bleeding and/or bleeding symptoms.
Sherif N; Goubran H; Hassan A; Burnouf T; El-Ekiaby M
Haemophilia; 2014 Mar; 20(2):238-43. PubMed ID: 24251732
[TBL] [Abstract][Full Text] [Related]
9. Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine-device use.
Christelle K; Norhayati MN; Jaafar SH
Cochrane Database Syst Rev; 2022 Aug; 8(8):CD006034. PubMed ID: 36017945
[TBL] [Abstract][Full Text] [Related]
10. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial.
Lukes AS; Moore KA; Muse KN; Gersten JK; Hecht BR; Edlund M; Richter HE; Eder SE; Attia GR; Patrick DL; Rubin A; Shangold GA
Obstet Gynecol; 2010 Oct; 116(4):865-875. PubMed ID: 20859150
[TBL] [Abstract][Full Text] [Related]
11. von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease.
Gill JC; Shapiro A; Valentino LA; Bernstein J; Friedman C; Nichols WL; Manco-Johnson M
Haemophilia; 2011 Nov; 17(6):895-905. PubMed ID: 21535320
[TBL] [Abstract][Full Text] [Related]
12. Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results.
Leebeek FWG; Peyvandi F; Escobar M; Tiede A; Castaman G; Wang M; Wynn T; Baptista J; Wang Y; Zhang J; Mellgård B; Özen G
Blood; 2022 Jul; 140(2):89-98. PubMed ID: 35439298
[TBL] [Abstract][Full Text] [Related]
13. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
Berntorp E; Windyga J;
Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
[TBL] [Abstract][Full Text] [Related]
14. Gynecologic and obstetric management of women with von Willebrand disease: summary of 3 systematic reviews of the literature.
Brignardello-Petersen R; El Alayli A; Husainat N; Kalot MA; Shahid S; Aljabirii Y; Britt A; Alturkmani H; El-Khechen H; Motaghi S; Roller J; Abdul-Kadir R; Couper S; Kouides P; Lavin M; Ozelo MC; Weyand A; James PD; Connell NT; Flood VH; Mustafa RA
Blood Adv; 2022 Jan; 6(1):228-237. PubMed ID: 34673921
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
Lillicrap D; Poon MC; Walker I; Xie F; Schwartz BA;
Thromb Haemost; 2002 Feb; 87(2):224-30. PubMed ID: 11858481
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy.
Gill JC; Ewenstein BM; Thompson AR; Mueller-Velten G; Schwartz BA;
Haemophilia; 2003 Nov; 9(6):688-95. PubMed ID: 14750934
[TBL] [Abstract][Full Text] [Related]
17. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease.
Gill JC; Castaman G; Windyga J; Kouides P; Ragni M; Leebeek FW; Obermann-Slupetzky O; Chapman M; Fritsch S; Pavlova BG; Presch I; Ewenstein B
Blood; 2015 Oct; 126(17):2038-46. PubMed ID: 26239086
[TBL] [Abstract][Full Text] [Related]
18. Antifibrinolytics for heavy menstrual bleeding.
Lethaby A; Farquhar C; Cooke I
Cochrane Database Syst Rev; 2000; (4):CD000249. PubMed ID: 11034679
[TBL] [Abstract][Full Text] [Related]
19. The spectrum and severity of bleeding in adolescents with low von Willebrand factor-associated heavy menstrual bleeding.
Srivaths L; Minard CG; O'Brien SH; Wheeler AP; Mullins E; Sharma M; Sidonio R; Jain S; Zia A; Ragni MV; Kulkarni R; Dietrich JE; Kouides PA
Blood Adv; 2020 Jul; 4(13):3209-3216. PubMed ID: 32663297
[TBL] [Abstract][Full Text] [Related]
20. Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network.
Abshire T; Cox-Gill J; Kempton CL; Leebeek FW; Carcao M; Kouides P; Donfield S; Berntorp E
J Thromb Haemost; 2015 Sep; 13(9):1585-9. PubMed ID: 25930155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
